AURX (Nuo Therapeutics) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


AURX Nuo Therapeutics Inc AURX
33 GF Score
Price $1.01
GF Value $4.25
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Nuo Therapeutics ROE % Adjusted to Book Value?

Nuo Therapeutics AURX 33 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates AURX with a GF Score™ of 33/100 and a GF Value™ of $4.25 (Possible Value Trap). The stock has 4 warning signs investors should review.

Nuo Therapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Nuo Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Nuo Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Nuo Therapeutics ROE % Adjusted to Book Value Related Terms

Nuo Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Nuo Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nuo Therapeutics ROE % Adjusted to Book Value Chart

Nuo Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -7.37 -8.21 -2.35 0.00

Nuo Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

AURX vs PDSB, LTRN, VERU: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Nuo Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuo Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuo Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Nuo Therapeutics's ROE % Adjusted to Book Value falls into.


AURX
33GF Score
Nuo Therapeutics Inc AURX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nuo Therapeutics ROE % Adjusted to Book Value Calculation

Nuo Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Nuo Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Nuo Therapeutics (AURX) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nuo Therapeutics and its competitors.
Is Nuo Therapeutics' ROE % Adjusted to Book Value too high?
Nuo Therapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Nuo Therapeutics has a GF Score™ of 33/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nuo Therapeutics' ROE % Adjusted to Book Value compare to PDSB and LTRN?
Nuo Therapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Nuo Therapeutics and its competitors. Nuo Therapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nuo Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Nuo Therapeutics (AURX) is currently considered Possible Value Trap. The stock's GF Value™ is $4.25, compared to a current price of $1.01 — trading 76.2% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.00%. Nuo Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Nuo Therapeutics (AURX), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nuo Therapeutics (AURX) Overvalued in 2026?

Based on GuruFocus' analysis, Nuo Therapeutics stock appears to be undervalued. The current stock price of $1.01 is trading 76.2% below its estimated GF Value™ of $4.25. GuruFocus considers Nuo Therapeutics to be Possible Value Trap.

Key valuation signals for AURX:

  • ROE % Adjusted to Book Value: 0.00%
  • GF Value™: $4.25 vs. price of $1.01 (76.2% below fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the AURX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nuo Therapeutics Business Description

Address 8285 El Rio Street, Suite 190, Houston, TX, USA, 77054
Nuo Therapeutics Inc is a commercial-stage medical device company engaged in developing and marketing products for chronic wound care. The company operates as a single segment focused on regenerative therapies that utilize autologous (patient-derived) biological materials to promote natural healing. Its primary commercial product is the Aurix System, a point-of-care technology that produces platelet-rich plasma (PRP) therapy from a patient's own blood for use in the treatment of chronic wounds.
33GF Score

Get the complete analysis for AURX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.01
Price
$4.25
GF Value